ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
193.02
0.00
(0.00%)
Cerrado 25 Diciembre 3:00PM
0.00
0.00
(0.00%)
Fuera de horario: -

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
193.02
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
193.02
Precio de Apertura
-
Hora
Última hora de negociación
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

AGN Últimas noticias

Aegon completes share buyback program

The Hague, January 31, 2023 - Aegon has completed the share buyback program announced on January 6, 2023, in relation to its obligations resulting from the share-based compensation plans for...

Aegon Extraordinary General Meeting approves combination of Aegon’s Dutch businesses with a.s.r.

The Hague, January 17, 2023 - Aegon N.V.'s Extraordinary Meeting of Shareholders (EGM) has today approved the strategic decision to combine Aegon’s Dutch pension, life and non-life insurance...

Aegon to repurchase shares for share-based compensation plans

The Hague, January 6, 2023 - Aegon announced today that it will repurchase common shares for an amount of EUR 42.5 million to meet its obligations resulting from the share-based compensation plans...

Aegon completes share buyback programs

The Hague, December 15, 2022 - Aegon has completed two share buyback programs, one aimed at neutralizing the dilutive effect of the 2022 interim dividend paid in shares and the second to return...

Aegon publishes agenda for Extraordinary General Meeting on January 17, 2023

The Hague, November 24, 2022 - Today, Aegon N.V. has published the Agenda and Shareholder Circular for its Extraordinary General Meeting of Shareholders (EGM) on Tuesday, January 17, 2023 at 14:00...

Aegon reports third quarter 2022 results

Please click here to access all 3Q 2022 results related documents. The Hague, November 10, 2022 - Maintaining high pace in implementing Aegon’s strategy Net loss of EUR 206 million driven mainly...

Aegon takes note of equity issuance by a.s.r.

The Hague, October 28, 2022 - Aegon has taken note of the issuance of approximately 10% additional shares that a.s.r. announced on October 28, 2022, as part of its funding in relation to the...

Aegon to combine its Dutch operations with a.s.r.

The Hague, October 27, 2022 - Agreement marks pivotal step towards Aegon’s ambition to build leaders in chosen markets Combination creates a leader in the Dutch pension, life, and non-life...

Aegon completes sale of 50% stake in joint venture with Liberbank to Unicaja Banco

The Hague, October 14, 2022 - Aegon announced today that it has successfully completed the divestment of its 50% stake in the Spanish insurance joint venture with Liberbank to Unicaja Banco. As...

Aegon to repurchase shares to neutralize 2022 interim dividend paid in shares

The Hague, September 27, 2022 - Aegon will repurchase common shares for an amount of EUR 133 million to neutralize the dilutive effect of the 2022 interim dividend paid in shares. These shares...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

AGN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Allergan?
El precio actual de las acciones de Allergan es US$ 193.02
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Allergan?
Allergan ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MPLNChurchill Capital Corp III
US$ 12.24
(94.90%)
2.11M
NEUENeuehealth Inc
US$ 7.54
(74.94%)
780.07k
SESSES AI Corporation
US$ 0.71
(36.33%)
48.69M
KOREKORE Group Holdings Inc
US$ 1.88
(27.89%)
297.19k
EVTLVertical Aerospace Ltd
US$ 8.96
(20.75%)
286.9k
VNCEVince Holding Corp
US$ 4.00
(-20.00%)
409.69k
DNMRDanimer Scientific Inc
US$ 3.23
(-15.22%)
123.46k
CDR-BCedar Realty Trust Inc
US$ 14.0301
(-10.34%)
8.45k
WSO.BWatsco Inc
US$ 489.70
(-8.47%)
11
MOGUMOGU Inc
US$ 2.18
(-8.02%)
3.55k
QBTSD Wave Quantum Inc
US$ 7.95
(-2.45%)
51.47M
BBAIBigBear ai Holdings Inc
US$ 3.73
(16.93%)
49.68M
SESSES AI Corporation
US$ 0.71
(36.33%)
48.69M
ACHRArcher Aviation Inc
US$ 10.80
(15.14%)
48.49M
FFord Motor Company
US$ 10.02
(1.21%)
29.1M

AGN Discussion

Ver más
ShadowVolcano37 ShadowVolcano37 7 meses hace
back in the day (2020) it was a promising company. no wonder it has been purchased by AbbVie. despite the allergy related name, they invented Botox!
👍️0
barnyarddog barnyarddog 3 años hace
193.00 Game-Changer: The FDA Approved Eye Drops That Replace Reading Glasses

The drops, known as pilocarpine, and sold by pharma outlet Allergan under the name “Vuity,” might help the 128 million people in the United States who are nearsighted.

One drop in each eye, according to the business, may enhance closeup eyesight for six to ten hours, according to CBS News.

https://www.zerohedge.com/medical/game-changer-fda-approved-eye-drops-replace-reading-glasses
👍️0
JustJack JustJack 4 años hace
Please don’t invest your grandkids money here.
👍️0
JustJack JustJack 4 años hace
It doesn't look to be trading?

Did you do any DD you can pass along?

anyone looking to buy today?
👍️0
JustJack JustJack 4 años hace
What happened here rcookr1?
👍️0
DewDiligence DewDiligence 5 años hace
That's a wrap!
👍️0
DewDiligence DewDiligence 5 años hace
ABBV completes $65B AGN acquisition:

https://www.allergan.com/News/Details/2020/05/AbbVie%20Inc%20Completes%20Acquisition%20of%20Allergan%20plc

The deal, announced in Jun 2019 (#msg-149577810), entitles each AGN share to receive 0.886 shares of ABBV plus $120.30 in cash, a nominal value of $194.69/sh (3% higher than the nominal value of $188.24/sh nominal value at the time of the deal announcement).
👍️0
DewDiligence DewDiligence 5 años hace
1Q20 worldwide Botox sales=$812.2M, -6% YoY, -20% QoQ*:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1578845/000156459020022386/agn-10q_20200331.htm

• US therapeutic: $395.8M (-1% YoY, -15% QoQ*)
• US cosmetic: $212.7M (-7% YoY, -22% QoQ*)
--
US total: $608.5M (65% therapeutic; 35% cosmetic) was 75% of worldwide total


• Ex-US therapeutic: $89.3M (-1% YoY, -13% QoQ*)
• Ex-US cosmetic: $114.4M (-21% YoY, -37% QoQ*)
--
Ex-US total: $203.7M (44% therapeutic; 56% cosmetic) was 25% of worldwide total


*Apart from the COVID-19 pandemic, Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
👍️0
DewDiligence DewDiligence 5 años hace
ABBV-AGN merger expected to close 5/8/20:

https://finance.yahoo.com/news/announcement-relating-outcome-court-sanction-105500126.html
👍️0
DewDiligence DewDiligence 5 años hace
Following FTC agreement, ABBV-AGN plan May 2020 merger closing:

https://www.prnewswire.com/news-releases/abbvie-and-allergan-sign-consent-decree-agreement-with-federal-trade-commission-staff-on-pending-transaction-301025767.html
👍️0
DewDiligence DewDiligence 5 años hace
ABBV-AGN receive EU approval for merger—US FTC approval still pending:

https://finance.yahoo.com/news/abbvie-allergan-receive-final-european-130000384.html
👍️0
DewDiligence DewDiligence 5 años hace
4Q19 worldwide Botox sales=$1.020B, +8% YoY, +10% QoQ*:

https://allergan.gcs-web.com/node/22536/pdf

• US therapeutic: $463.0M (+7% YoY, +7% QoQ*)
• US cosmetic: $271.8M (+6% YoY, +14% QoQ*)
--
US total: $734.8M (63% therapeutic; 37% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $102.5M (+9% YoY, +9% QoQ*)
• Ex-US cosmetic: $182.9M (+20% YoY, +10% QoQ*)
--
Ex-US total: $285.4M (36% therapeutic; 64% cosmetic) was 28% of worldwide total


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
👍️0
DewDiligence DewDiligence 5 años hace
FDA approves AGN’s Ubrelvy (ubrogepant) for acute migraine treatment:

https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine

Ubrelvy may do well in the crowded CGRP arena because it’s oral.

AGN has a second oral CGRP candidate, Atogepant, in development for migraine prevention.

AGN acquired both drugs from MRK in 2015 for what now appears to be a very reasonable price (#msg-115206907).
👍️0
DewDiligence DewDiligence 5 años hace
3Q19 worldwide Botox sales=$928.7M, +6% YoY, -5% QoQ*:

https://www.allergan.com/News/Details/2019/11/Allergan%20Reports%20Third%20Quarter%202019%20Financial%20Results

• US therapeutic: $431.6M (+6% YoY, -3% QoQ*)
• US cosmetic: $237.6M (+10% YoY, -6% QoQ*)
--
US total: $669.2M (64% therapeutic; 36% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $93.9M (+5% YoY [constant currency], -5% QoQ*)
• Ex-US cosmetic: $165.6M (+6% YoY [constant currency], -6% QoQ*)
--
Ex-US total: $259.5M (36% therapeutic; 64% cosmetic) was 28% of worldwide total


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
👍️0
DewDiligence DewDiligence 5 años hace
2Q19 worldwide Botox sales=$974.0M, +4% YoY, +12% QoQ*:

https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Reports-Second-Quarter-2019-Financial-Res

• US therapeutic: $447.0M (+6% YoY, +12% QoQ)
• US cosmetic: $252.4M (+7% YoY, +10% QoQ)
--
US total: $699.4M (64% therapeutic; 36% cosmetic)


• Ex-US therapeutic: $98.8M (+1% YoY [constant currency], +5% QoQ)
• Ex-US cosmetic: $175.8M (+11% YoY [constant currency], +19% QoQ)
--
Ex-US total: $274.6M (36% therapeutic; 64% cosmetic)


*Botox sales are seasonally stronger in the second and fourth calendar quarters than in the first and third quarters.
👍️0
jdlamont jdlamont 6 años hace
agn looking to buy EYEN. still a no brainer
👍️0
DewDiligence DewDiligence 6 años hace
LOL. These lawsuit PRs are pre-written fill-in-the-blanks forms ready to go at any moment.
👍️0
whytestocks whytestocks 6 años hace
News: $AGN Allergan Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Allergan plc is Fair to Shareholders - AGN

NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Allergan plc (NYSE: AGN) to AbbVie Inc. (“AbbVie”) is fair to Allergan shareholders. On behalf of Allergan shareholders, Halper Sadeh LLP may s...

Find out more https://marketwirenews.com/news-releases/allergan-merger-investigation-halper-sadeh-llp-announces-investigation-into-whether-the-sale-of-allergan-plc-is-fair-to-shareholders-agn-8411800.html
👍️0
DewDiligence DewDiligence 6 años hace
ABBV-AGN CC slides:

https://investors.abbvie.com/static-files/7b4c052f-bf32-4917-a239-0c1c9416550a
👍️0
whytestocks whytestocks 6 años hace
News: $AGN AbbVie to Acquire Allergan in Transformative Move for Both Companies

NORTH CHICAGO , Ill. and DUBLIN , June 25, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Allergan plc (NYSE: AGN)  announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction...

In case you are interested https://marketwirenews.com/news-releases/abbvie-to-acquire-allergan-in-transformative-move-for-both-companies-8409708.html
👍️0
DewDiligence DewDiligence 6 años hace
RF-frequency devices for aesthetic applications go back at least 15 years to a company called Thermage (#msg-3876193). The THRM device never sold well and ended up being a swanky coat hanger at many doctor’s offices (#msg-11593419, #msg-29182011). THRM, which became SLTM, was eventually bought by Valeant Pharmaceuticals (the ultimate roll-up company) in 2013.

THRM’s device used RF-frequency waves to heat cells. I’m unclear how RF can used to cool cells, as AGN’s CoolTone supposedly does.
👍️0
semi_infinite semi_infinite 6 años hace
The Zeltiq device is cryogenic and seems to work according to a couple of relatives that have tried it. The cool tone device is magnetic and not as proprietary. There are already devices on the market such as the one below. I would like to see the data supporting the claim that 1.35T gives better results than 0.9T.

https://www.venusconcept.com/en-us/venus-freeze-plus.htm

https://www.venusconcept.com/en-us/venus-legacy.htm
👍️0
RichardSawars RichardSawars 6 años hace
~ 60% more effective then laser removal. Shorter treatments (2 months average vs ~ 1 year avg removal) without inflicting pain on clients.

Do some more Dewdiligence on it.
👍️0
DewDiligence DewDiligence 6 años hace
[OT]—I would question the business plan of any company that’s working on cellulite.

What’s differentiating about SOLY as compared to tattoo removal by laser?
👍️0
RichardSawars RichardSawars 6 años hace
In regards to AGN.. Has anyone heard of SOLY yet? The board of the company was recently involved with a similar company that developed a breakthrough fat reduction therapy that was purchased by AGN for 56$ ps or 2.4B.

$SOLY has patented technology on industry leading tattoo removal (RAP) & they announce their trial results for cellulite removal today.
👍️0
DewDiligence DewDiligence 6 años hace
AGN 1Q19 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-123003495.html
👍️0
DewDiligence DewDiligence 6 años hace
AGN 1Q19 CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzg1NzN8Q2hpbGRJRD03MDY1MjY=
👍️0
DewDiligence DewDiligence 6 años hace
(From AGN’s PR)—1Q19 worldwide Botox sales=$868.4M, +6% YoY (-8% QoQ*):

• US therapeutic: $397.6M (+6 YoY, -8% QoQ*)
• US cosmetic: $229.5M (+17% YoY, -11% QoQ*)
--
Total US sales: $627.1M (63% therapeutic, 37% cosmetic)


• Ex-US therapeutic: $93.9 (+7% YoY, -3% QoQ*)
• Ex-US cosmetic: $147.4M (+9% YoY, -7% QoQ*)
--
Total ex-US sales = $241.3M (39% therapeutic, 61% cosmetic)


*The 1Q19 QoQ decline relative to 4Q18 was expected; Botox is seasonally stronger in the second and fourth quarters of the calendar year.
👍️0
DewDiligence DewDiligence 6 años hace
AGN 1Q19 results:

https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Reports-First-Quarter-2019-Financial-Resu
👍️0
DewDiligence DewDiligence 6 años hace
Abicipar pegol (a/k/a DARPin) shows 8.9% ocular inflammation in open-label study with new manufacturing process—lower than the 15% rate in prior phase-3 trials, but still too high to be competitive (IMO):

https://finance.yahoo.com/news/allergan-molecular-partners-announce-topline-110000485.html

AGN, by its own admission, was aiming for an inflammation rate in the low-to-mid single digits.
👍️0
DewDiligence DewDiligence 6 años hace
Three phase-3 Rapastinel trials stopped for futility:

https://www.prnewswire.com/news-releases/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html
👍️0
DewDiligence DewDiligence 6 años hace
AGN 4Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-213849663.html
👍️0
DewDiligence DewDiligence 6 años hace
AGN 4Q18 CC slides:

https://www.allergan.com/news/assets/q4-2018-earnings-deck_final
👍️0
DewDiligence DewDiligence 6 años hace
AGN 4Q18 results:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzcwMDh8Q2hpbGRJRD03MDM1MTE=
👍️0
whytestocks whytestocks 6 años hace
News: $AGN CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care

DUBLIN , Jan. 15, 2019 /PRNewswire/ -- Television personality on Bravo's "The Real Housewives of New York City ", philanthropist, fashion lifestyle entrepreneur and mom, Sonja Morgan , is partnering with CoolSculpting, owned by Allergan plc (NYSE: AGN), as the face of the brand's l...

Read the whole news https://marketwirenews.com/news-releases/coolsculpting-xae-and-sonja-morgan-partner-to-get-real-about-self-care-6831048.html
👍️0
DewDiligence DewDiligence 6 años hace
AGN -7% on permanent recall of “textured” breast implants in Europe:

https://finance.yahoo.com/news/allergan-suspends-sales-withdraws-supply-133000863.html
👍️0
DewDiligence DewDiligence 6 años hace
AGN 3Q18 CC transcript:

https://finance.yahoo.com/news/allergan-plc-agn-q3-2018-164449472.html
👍️0
DewDiligence DewDiligence 6 años hace
Reason for today’s selloff: #msg-144555471.
👍️0
DewDiligence DewDiligence 6 años hace
AGN 3Q18 results items…

PR:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzU1Mjd8Q2hpbGRJRD03MDEwNzI=

CC slides:
https://www.allergan.com/news/assets/final-deck-q3-2018-10-30-2018.aspx
👍️0
DewDiligence DewDiligence 6 años hace
AGN slides from AAO webcast:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzU4MTF8Q2hpbGRJRD03MDA5ODI=
👍️0
DewDiligence DewDiligence 6 años hace
AGN slides from Medical Aesthetics Day:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzQ0Nzh8Q2hpbGRJRD02OTk5MDQ=
👍️0
DewDiligence DewDiligence 6 años hace
Re: AGN's internal long-acting toxin

#msg-143560931
#msg-143560695
👍️0
DewDiligence DewDiligence 6 años hace
AGN acquires (private) Bonti for $195M plus contingencies:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143556549

Bonti’s product candidate is a type-E botulinum toxin, which is an altogether different animal from type-A botulinum toxins such as Botox and RVNC’s RT002.

I previously commented on Bonti in #msg-137948777 and #msg-137955390.
👍️0
DewDiligence DewDiligence 6 años hace
AGN receives CRL for Ulipristal treatment for uterine fibroids:

https://www.prnewswire.com/news-releases/allergan-receives-complete-response-letter-from-the-us-food-and-drug-administration-for-ulipristal-acetate-new-drug-application-300700400.html
👍️0
DewDiligence DewDiligence 6 años hace
AGN, EDIT announce mutual opt-ins on EDIT-101: #msg-142720697.
👍️0
DewDiligence DewDiligence 6 años hace
More granularity of 2Q18 Botox sales: #msg-142479825.
👍️0
DewDiligence DewDiligence 6 años hace
Transcript of AGN 2Q18 CC:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-213321827.html
👍️0
DewDiligence DewDiligence 6 años hace
AGN 2Q18 items…

PR:
https://finance.yahoo.com/news/allergan-reports-strong-second-quarter-103000561.html

CC slides:
http://www.allergan.com/news/assets/q2-2018-earnings-presentation.pdf
👍️0
DewDiligence DewDiligence 6 años hace
AGN/MOLN.SW report phase-3 AMD data for Abicipar (a/k/a DARPin):

#msg-142311304
👍️0
DewDiligence DewDiligence 7 años hace
AGN 1Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-224140279.html
👍️0

Su Consulta Reciente

Delayed Upgrade Clock